Fibroblast Activation Protein Inhibitor Theranostics

Rainer Hamacher(Technical University of Munich), Wolfgang P. Fendler(Essen University Hospital), Hans‐Ulrich Schildhaus(University of Cologne), Kim M. Pabst(Klinik und Poliklinik für Nuklearmedizin), Phyllis F. Cheung(German Cancer Research Center), Helena Lanzafame(Düsseldorf University Hospital), Jens T. Siveke(German Cancer Research Center), Lukas Kessler(Deutschen Konsortium für Translationale Krebsforschung), Ken Herrmann(Klinikum rechts der Isar), Ilektra A. Mavroeidi(German Cancer Research Center), Sebastian Bauer(University of Duisburg-Essen)
PET Clinics
March 28, 2023
10.1016/j.cpet.2023.02.008
Cited by 14

Related Papers

Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
|Annals of Oncology|2021|978
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
|The Lancet Oncology|2007|808
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2016|766